A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Conditions:   Small Cell Lung Carcinoma (SCLC);   Neuroendocrine Neoplasms Interventions:   Drug: BI 764532;   Drug: Ezabenlimab Sponsor:   Boehringer Ingelheim Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials